MERTK Inhibition Selectively Activates a DC–T-Cell Axis to Provide Anti-Leukemia Immunity

Host Mertk knock-out or MERTK inhibitor MRX-2843 increased CD8α+ dendritic cells with enhanced antigen-presentation capacity in the leukemia microenvironment and inhibited leukemogenesis.